Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lithospermum (specifically *Lithospermum erythrorhizon*, known as Zicao in Chinese medicine) is a botanical drug derived from the dried root of the plant. It is widely used in Traditional Chinese Medicine (TCM) and Japanese Kampo medicine for its cooling, blood-detoxifying, and wound-healing properties. The primary active constituents are naphthoquinone pigments, including shikonin and its derivatives like acetylshikonin. These compounds possess significant anti-inflammatory, antimicrobial, antioxidant, and potential antineoplastic activities. Shikonin acts by inhibiting pro-inflammatory signaling pathways such as NF-κB and MAPK, and reducing the expression of cytokines like TNF-α. Topically, it is a common ingredient in ointments for treating burns, eczema, and psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lithospermum erythrorhizon root.